Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Essential Hypertension
Interventions: Placebo Single IV (Intravenous) Infusion, Experimental: Single IV Infusion Vasomera (PB1046); Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40,563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemia
Interventions: telephone counseling; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 40 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Elevated Blood Pressure, Hypertension
Interventions: Pumpkin Seed Oil, Placebo; Other
Lead sponsor: Marymount University; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: Pulmonary Arterial Hypertension, Healthy
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension
Interventions: Erythropoietin and Hydroxyurea; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: Aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pulmonary Arterial Hypertension (PAH)
Interventions: Allogeneic Human Cardiosphere-Derived Stem Cells, Placebo; Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Interventions: ER-100 epigenetic therapy; Genetic
Lead sponsor: Life Biosciences Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Glendale, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Beraprost Sodium 314d Modified Release Tablets, Placebo; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 69
States / cities: Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more

Conditions: Liver Cirrhosis, Portal Hypertension, Ascites
Interventions: TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis, LVP, TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol; Device · Procedure
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Tucson, Arizona • Baltimore, Maryland

Conditions: Food Insecurity, Diabetes in Adults, Hypertension (HTN)
Interventions: Food is Medicine; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Arteriosclerosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension, Hypertension in Pregnancy, Diabetes Mellitus, Gestational Diabetes, Obesity, Depressive Disorder, Anxiety Disorders
Interventions: Default appointment scheduling, Targeted messaging, Nudge Reminders; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 32
States / cities: Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more

Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions: HTN Educational Video, Visual Echocardiogram Image Clips, Mobile Health and Remote BP monitoring, Post-Acute Care HTN Transition consultation (PACHT-c); Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 9
States / cities: Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more

Conditions: Hypertension
Interventions: Metoprolol, Nebivolol; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Hypertension
Interventions: Clevidipine; Drug
Lead sponsor: Mario Ammirati; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pulmonary Hypertension
Interventions: Inspiratory Muscle Strength Training; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 815 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 36
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more

Conditions: Glaucoma, Glaucoma, Open Angle
Interventions: AqueSys XEN 45 Glaucoma Implant; Device
Lead sponsor: AqueSys, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Montebello, California + 9 more

Conditions: Hypertension
Interventions: Aerobic Exercise, Relaxation; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 45 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type 2 Diabetes, Hypertension, Hyperlipidemia
Interventions: home health/primary care collaboration; Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 30 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension

Improving Medication Adherence in Comorbid Conditions

The Effects of Pumpkin Seed Oil Supplementation on Cardiovascular Function in Postmenopausal Women.

Right Ventricular Metabolism in Pulmonary Arterial Hypertension

Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

Beraprost-314d Added-on to Tyvaso® (BEAT)

Early TIPS for Ascites Study

RUSH Food is Medicine Veggie Rx - GusNIP Produce Prescription

Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease

Bridging the Gap From Postpartum to Primary Care

DE-117 Spectrum 5 Study

Targeting of UnControlled Hypertension in Emergency Department

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment

The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy

Pulmonary Hypertension Inspiratory Training

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma

Physical Fitness, Cardiovascular and Brain Health

Controlling Hypertension in Diabetes- Feasibility Study